Use access key #2 to skip to page content.

portefeuille (99.60)

PBTH

Recs

1

March 28, 2010 – Comments (4)

On 02/02/10 zzlangerhans wrote this about PROLOR Biotech.

---------------
Pitch by: zzlangerhans 2/02/10 12:06 PM
OK, let's see if this run has any gas left in it. When considering green thumbing an OB like Prolor, I feel like the main task is identifying the problem with the stock. The underlying science seems justified. The company is developing protein therapeutics that have been modified with the naturally-occurring CTP amino acid sequence to extend in vivo half-life. They are targeting large markets for growth hormone, interferon, erythropoietin and other compounds that currently require frequent injections. New formulations that are equally effective but dramatically reduce the frequency of injections would likely replace the current standard of care. The recent upward run was due to EMEA approval of Merck's FSH-CTP, which independently validated Prolor's reason for existence. The company recently completed their first phase I safety trial, but has not yet generated any efficacy data from clinical trials.

What I don't particularly like is that the company went public earlier this year through a shell merger with a previously busted company that I can't find any info about. Philip Frost seems to be the main financial backer and I'm not a fan of the opacity and gyrations of the other stocks he has been involved with. I can't determine from the company's financial statements what their cash position is, but it seems to be low.

Ultimately this is a CAPS-only bet that the financial condition of the company is sufficiently stable to allow some further inflation in share price before the inevitable first crash occurs.
---------------

(from here)

 

I adopted the call.

---------------

#990) On February 12, 2010 at 11:42 AM, portefeuille (99.97) wrote: PBTH:US - 2.60 - outperform
---------------

(from here

 

01/29/10 PROLOR BIOTECH REPORTS MERCK RECEIVES FINAL MARKETING AUTHORIZATION IN EUROPE FOR LONG-ACTING CTP-MODIFIED FERTILITY TREATMENT ELONVA® (FSH-CTP) (pdf)  

02/08/10 PROLOR Biotech's presentation at the 12th Annual BIO-CEO & Investor Conference 

03/18/10 PROLOR BIOTECH ANNOUNCES SALE OF $24.4 MILLION OF COMMON STOCK (pdf) 

03/25/10 PROLOR BIOTECH ANNOUNCES NYSE AMEX LISTING (pdf)
 


enlarge
 



enlarge
 



enlarge
 

 

I think it is one of the more interesting small cap biotech companies.

4 Comments – Post Your Own

#1) On March 28, 2010 at 5:27 PM, portefeuille (99.60) wrote:

Prolor Biotech: A Solution to Big Pharma’s Problems

---------------

PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group

NES-ZIONA, Israel, July 24 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH), formerly Modigene Inc., today announced that it has entered into stock purchase agreements with private investors to sell up to $10 million of the company's newly issued 10% cumulative convertible preferred stock at a price of $2.00 per share. As part of the agreements, the company closed on the issuance of one million preferred shares for proceeds of $2 million. The preferred stock investors include members of The Frost Group, LLC, including Dr. Phillip Frost, who is also the chairman of the board of PROLOR, and two other PROLOR directors, Dr. Jane Hsiao and Steven Rubin. In conjunction with this new agreement, PROLOR's existing line of credit agreement with The Frost Group has been terminated.

 

"After working closely with the PROLOR team as chairman over the past two years, I am very pleased to be expanding my investment in the company at this exciting time in its development, together with other members of The Frost Group," said Dr. Frost. "I look forward to continuing to work with the board and management to help build PROLOR into a significant player in the therapeutic proteins market."

 

The stock purchase agreement allows PROLOR at its sole discretion to issue up to an additional $8 million of preferred shares in one or more closings at any time before March 25, 2013. Shares issued pursuant to the agreement, including the shares of PROLOR's common stock into which the preferred shares may be converted, have not been and will not be registered under applicable securities laws and are therefore restricted securities - PROLOR has not granted any registration rights under the stock purchase agreement. Additionally, all shares acquired by the investors under this agreement are subject to a one-year lock-up. The stock purchase agreement does not include any warrants to investors.

 

"This new infusion of equity capital comes at a critical time for PROLOR, as we are approaching significant milestones in the development of our long-acting human growth hormone candidate that has the potential to significantly decrease the frequency of administration of this important injectable drug," said Shai Novik, president of PROLOR. "We believe that the $2 million in preferred stock financing from members of The Frost Group, along with the option to obtain up to an additional $8 million at our sole discretion, is a positive development for the company.

...

---------------

(from here (pdf))

"Phillip Frost won't move Teva to US"

Report this comment
#2) On March 28, 2010 at 7:57 PM, portefeuille (99.60) wrote:

---------------

New Insight Into Multiple-Sclerosis Treatment

...

The drug also causes flu-like symptoms like aches, fever and muscle pain that can last for hours. The side effects often discourage patients from taking the medicine as prescribed, especially since it can take two years or more before it becomes apparent if it is helping.

...

---------------

---------------

Many MS patients currently rely on IFN-beta to keep their disease in check, but to do so they must inject the drug frequently, with the attendant risk of adverse reactions that often accompany these injections.  By potentially allowing these patients to dramatically reduce the required injection frequency and the injected dose, PROLOR believes that its IFN-beta-CTP could significantly enhance patients' quality of life.

---------------

(from here)

also see slide 18/26 of the presentation mentioned above.

Report this comment
#3) On July 04, 2010 at 12:23 PM, portefeuille (99.60) wrote:



enlarge

 



enlarge

Report this comment
#4) On July 04, 2010 at 12:26 PM, portefeuille (99.60) wrote:

PROLOR Biotech's presentation at the Jefferies 2010 Global Life Sciences Conference

Report this comment

Featured Broker Partners


Advertisement